Advaxis Seeks FDA Approval to Begin Phase 1 Trial of its ADXS-504 Immunotherapy for Prostate Cancer
News
Advaxis is seeking permission from the U.S. Food and Drug Administration (FDA) to start the first Phase 1 clinical trial of ADXS-504, a potential immunotherapy for prostate cancer. Cancer cells ... Read more